Wedbush Securities Inc Crispr Therapeutics Ag Transaction History

Wedbush Securities Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	BUY	$51.17 - $68.18 $18,728 - $24,953	366 Added 6.89%	5,677 $307,000
Q1 2024 May 14, 2024	BUY	$60.67 - $89.12 $69,952 - $102,755	1,153 Added 27.73%	5,311 $362,000
Q4 2023 Feb 12, 2024	BUY	$38.62 - $72.18 $160,581 - $300,124	4,158 New	4,158 $260,000
Q2 2023 Aug 14, 2023	SELL	$43.47 - $67.77 $51,642 - $80,510	-1,188 Reduced 23.98%	3,767 $211,000
Q1 2023 May 09, 2023	BUY	$41.0 - $56.12 $203,155 - $278,074	4,955 New	4,955 $224,000
Q3 2022 Oct 18, 2022	SELL	$61.1 - $83.78 $185,927 - $254,942	-3,043 Reduced 34.98%	5,656 $369,000
Q1 2022 Apr 19, 2022	SELL	$53.19 - $79.24 $26,914 - $40,095	-506 Reduced 5.5%	8,699 $546,000
Q4 2021 Jan 13, 2022	BUY	$70.09 - $111.29 $63,781 - $101,273	910 Added 10.97%	9,205 $697,000
Q3 2021 Oct 08, 2021	SELL	$110.2 - $156.64 $28,982 - $41,196	-263 Reduced 3.07%	8,295 $928,000
Q2 2021 Jul 27, 2021	SELL	$100.84 - $161.89 $10,184 - $16,350	-101 Reduced 1.17%	8,558 $1.39 Million
Q1 2021 Apr 26, 2021	BUY	$110.72 - $210.04 $958,724 - $1.82 Million	8,659 New	8,659 $1.06 Million

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.23B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.